Home | Services | Products | Support | Useful Documents | Experience | Staff | Opportunities  
 
   
News
Ross McLeod Joins Macquarie University’s Centre for the Health Economy as a Senior Research Fellow
Ross McLeod Engaged to Examine the Cost-Effectiveness of the World Health Organization’s South Asia Region Tuberculosis Strategy
eSYS Development Engaged to Estimate the Costs of Australian Food and Wine fraud in Asia
Ross McLeod Engaged by the Royal Australasian College of Surgeons (RACS) as a Market Access and Health Economics Advisor
Ross McLeod Joins the University of Sydney’s Human Research Ethics Committee
eSYS Development in Association with Murawin and the Human Capital Alliance Engaged to Undertake a Review of NSW’s Aboriginal Maternal and Infant Health Service
Midterm Review of the Papua New Guinea: Rural Primary Health Services Delivery Project
eSYS Development Engaged by the International Livestock Research Institute to Assess the Economic Impact of the Proposed Agri-Food Systems CGIAR Research Program
Review of Deflators and Capital Accounting in the Health Expenditure Australian Series
Triple Line Costs of Invasive Pests in NSW and Australia
Health Human Resources Sector Development Program in Viet Nam
Evaluation of the CGIAR Research Program on Dryland Systems
Country partnership strategy 2016 – 2020 for Viet Nam
Strengthening of Preventive Health Services in Vietnam
Review of Papua New Guinea Country Strategy for the Asian Development Bank
HTA Economic Approach for Assessing Hypofractionated Radiotherapy
Undertake Pre-Assessments of 2014 GAVI Health System Strengthening (HSS) Country Applications
Asia-Pacific Leaders Alliance to Combat Malaria Financing Taskforce
Evaluation of the Pacific HIV and STI Response Fund
Health Impact Assessment (HIA) Development for the Asian Development Bank
Mid-term Review of the Pacific Statistics Strategy
Indonesia Decentralized Health Services Project Evaluation
Ross McLeod part of evaluation team for 2012 review of Global Fund
HIV/AIDS Prevention Among Youth in the Socialist Republic of Viet Nam
Ross McLeod joins the GAVI Independent Review Committee

Capacity Building for HIV/AIDS Prevention in Lao and Vietnam

Value for Money Analysis of AusAid's new ...
Australian Illicit Drug Budgets
Cost Analysis of Western Sydney Needle and Syringe Program
Ross McLeod Visiting Fellow at Oxford University
Evaluation of Asian Development Bank Rural Health Project
Evaluation of Asian Development Bank Health Care ...
Financial Analysis of the FMD ...
Independent Evaluation of AusAid's Tibet ...
Economics of Counterfeit ...
The First Regional National ...
Open for Business in Vietnam
Monitoring the Response ...
Health Insurance Development in the Philippines
Environment
Health
Agriculture
 
 
 

Latest News  
   
Economics of Counterfeit Infectious Disease Medicines in the Mekong
  eSYS Development has just commenced a study examining the extent of the fake drug problem in the Mekong region for the Asian Development Bank. Counterfeit medicines are deliberately and fraudulently mislabelled branded and generic products. The US based Centre for Medicines in the Public Interest predicts that counterfeit drug sales will reach US$ 75 billion globally in 2010, an increase of more than 90% from 2005. Regional and national estimates are hindered by the lack of a systematic evaluation of the problem. Currently, in Asia, the sources of information available include reports from national authorities such as drug regulatory and enforcement agencies, ad hoc studies conducted on a specific geographical area or therapeutic category, reports from the pharmaceutical sector,
reports from NGOs and surveys. The overall aim of the study is to review and collate existing data about the prevalence of counterfeit HIV, TB and malaria medicines in Mekong region and economically quantify their impact. Quantification will focus on estimating the financial value of counterfeit drug sales, relative to the overall market size for medicines for these infectious diseases, along with estimating the economic costs to households and overall national economies from the usage of drugs with low efficacy.

Previous page

Next Page